{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hse:00544:a retrieved successfully",
    "request_url": "https://api.moalmanac.org/indications?indication_id=ind%3Ahse%3A00544%3Aa",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.001668,
    "timestamp_received": "2026-11-09T16:13:54.272218Z",
    "timestamp_returned": "2026-11-09T16:13:54.273886Z",
    "trace_id": "c09bc72d-6260-470e-b073-16ddf3122b76"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-10-08"
  },
  "data": [
    {
      "id": "ind:hse:00544:a",
      "type": "Indication",
      "description": "Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.",
      "contributions": [
        {
          "id": "ctrb:vanallenlab:2024-01-16:0",
          "type": "Contribution",
          "description": "Adding HSE approvals for reimbursement to database",
          "date": "2024-01-16",
          "contributor": {
            "id": "agent:user:vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute"
          }
        },
        {
          "id": "ctrb:hse:2019-03-01:0",
          "type": "Contribution",
          "description": "Indication approved for reimbursement.",
          "date": "2019-03-01",
          "contributor": {
            "id": "agent:org:hse",
            "type": "Agent",
            "agentType": "organization",
            "name": "Health Service Executive",
            "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
          }
        }
      ],
      "reportedIn": [
        {
          "id": "doc:hse:00544",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Atezolizumab Monotherapy. NCCP National SACT Regimen. HSE.",
          "title": null,
          "aliases": [],
          "description": "Atezolizumab Monotherapy, 2025, version number 14, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6644/544_v14_Atezolizumab_21_Day_Monotherapy.pdf",
          "urls": [
            "https://healthservice.hse.ie/documents/6644/544_v14_Atezolizumab_21_Day_Monotherapy.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "agent:org:hse",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Service Executive",
                "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland."
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": null,
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": null,
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "publication_date",
              "value": "2024-06-14",
              "description": "The publication date for the document."
            },
            {
              "name": "regulatory_identifier",
              "value": null,
              "description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "extensions": [
        {
          "name": "status",
          "value": "Approved",
          "description": "Current approval status."
        },
        {
          "name": "statement description",
          "value": "The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab for reimbursement as a monotherapy treatment option for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. The regimen further states that patients with EGFR mutations or an ALK fusion oncogene are required to have received prior tyrosine kinase inhibitor therapy.",
          "description": "The description text for all Statements derived from this Indication."
        },
        {
          "name": "reimbursement_scheme",
          "value": "ODMS",
          "description": "Current scheme used to reimburse indication."
        },
        {
          "name": "reimbursement_comment",
          "value": "ODMS; 2019-03-01 (IV); 2024-06-01 (SC)",
          "description": "More details about the current reimbursement scheme(s)."
        }
      ]
    }
  ]
}